Wupeng Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wupeng Liao has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Wai Shiu Fred Wong
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore
7 shared publications Caris Tan Qi Hui
Advanced imaging and Histology Core, Immunology Program, Life Science Institute National University of Singapore Singapore
2 shared publications- Caroline Sévoz-Couche
Inserm UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université Paris France
2 shared publications Hazel Yu Ci Foo
National University of Singapore Yong Loo Lin School of Medicine
2 shared publicationsIsabelle Bonne
Electron Microscopy Unit, Yong Loo Lin School of Medicine National University of Singapore Singapore
2 shared publicationsWendy Yen Xian Peh
The N.1 Institute for Health National University of Singapore Singapore
2 shared publications
Latest Publications
- 3 July 2025
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (7)
Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive incurable lung disease characterized by chronic inflammation and fibrosis, with innate immune cells such as neutrophils and macrophages playing central roles in its pathogenesis. This review explores the involvement of these immune cells in the inflammatory process of IPF, focusing on their contribution to disrupted tissue repair and impaired resolution. The balance between host defense mechanisms, including leukocyte recruitment, and the release of proresolving mediators is crucial for maintaining healthy tissue function and returning to preinflammatory states. We highlight the importance of inflammation resolution to prevent an overactive immune response, which can lead to irreversible fibrosis. Specialized proresolving mediators, including lipoxins, resolvins, protectins, and maresins, are discussed in terms of their regulatory effects on neutrophils and macrophages in IPF. These mediators exhibit potent anti-inflammatory actions, which can modulate the immune response and promote the resolution of inflammation. Overall, this review underscores the significance of immune modulation in IPF, with a focus on the therapeutic potential of specialized proresolving mediators in controlling the inflammatory response and preventing fibrosis progression. Future research into the antifibrotic properties of SPMs and their impact on innate immune cell regulation holds promise for novel therapeutic strategies in IPF treatment.
- 3 July 2025
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (7)
Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive incurable lung disease characterized by chronic inflammation and fibrosis, with innate immune cells such as neutrophils and macrophages playing central roles in its pathogenesis. This review explores the involvement of these immune cells in the inflammatory process of IPF, focusing on their contribution to disrupted tissue repair and impaired resolution. The balance between host defense mechanisms, including leukocyte recruitment, and the release of proresolving mediators is crucial for maintaining healthy tissue function and returning to preinflammatory states. We highlight the importance of inflammation resolution to prevent an overactive immune response, which can lead to irreversible fibrosis. Specialized proresolving mediators, including lipoxins, resolvins, protectins, and maresins, are discussed in terms of their regulatory effects on neutrophils and macrophages in IPF. These mediators exhibit potent anti-inflammatory actions, which can modulate the immune response and promote the resolution of inflammation. Overall, this review underscores the significance of immune modulation in IPF, with a focus on the therapeutic potential of specialized proresolving mediators in controlling the inflammatory response and preventing fibrosis progression. Future research into the antifibrotic properties of SPMs and their impact on innate immune cell regulation holds promise for novel therapeutic strategies in IPF treatment.
- Open Access
- 29 April 2025
- Published by Elsevier in Pharmacological Research
- Vol. 216, 107756
Calcaratarin D, a labdane diterpenoid, attenuates bleomycin-induced pulmonary fibrosis by blocking Wnt/β-catenin signaling pathway
- 29 April 2025
- Published by Elsevier in Pharmacological Research
- Vol. 216, 107756
Open AccessCalcaratarin D, a labdane diterpenoid, attenuates bleomycin-induced pulmonary fibrosis by blocking Wnt/β-catenin signaling pathway
- Open Access
- 2 March 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (13) , 1916-1934
Direct vagus nerve stimulation: A new tool to control allergic airway inflammation through α7 nicotinic acetylcholine receptor
Background and Purpose: Asthma is characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness. The use of nicotinic agents to mimic the cholinergic anti‐inflammatory pathway (CAP) controls experimental asthma. Yet, the effects of vagus nerve stimulation (VNS)‐induced CAP on allergic inflammation remain unknown.Experimental Approach: BALB/c mice were sensitized and challenged with house dust mite (HDM) extract and treated with active VNS (5 Hz, 0.5 ms, 0.05–1 mA). Bronchoalveolar lavage (BAL) fluid was assessed for total and differential cell counts and cytokine levels. Lungs were examined by histopathology and electron microscopy.Key Results: In the HDM mouse asthma model, VNS at intensities equal to or above 0.1 mA (VNS 0.1) but not sham VNS reduced BAL fluid differential cell counts and alveolar macrophages expressing α7 nicotinic receptors (α7nAChR), goblet cell hyperplasia, and collagen deposition. Besides, VNS 0.1 also abated HDM‐induced elevation of type 2 cytokines IL‐4 and IL‐5 and was found to block the phosphorylation of transcription factor STAT6 and expression level of IRF4 in total lung lysates. Finally, VNS 0.1 abrogated methacholine‐induced hyperresponsiveness in asthma mice. Prior administration of α‐bungarotoxin, a specific inhibitor of α7nAChR, but not propranolol, a specific inhibitor of β2‐adrenoceptors, abolished the therapeutic effects of VNS 0.1.Conclusion and Implications: Our data revealed the protective effects of VNS on various clinical features in allergic airway inflammation model. VNS, a clinically approved therapy for depression and epilepsy, appears to be a promising new strategy for controlling allergic asthma.
- 2 March 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (13) , 1916-1934
Open AccessDirect vagus nerve stimulation: A new tool to control allergic airway inflammation through α7 nicotinic acetylcholine receptor
Background and Purpose: Asthma is characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness. The use of nicotinic agents to mimic the cholinergic anti‐inflammatory pathway (CAP) controls experimental asthma. Yet, the effects of vagus nerve stimulation (VNS)‐induced CAP on allergic inflammation remain unknown.Experimental Approach: BALB/c mice were sensitized and challenged with house dust mite (HDM) extract and treated with active VNS (5 Hz, 0.5 ms, 0.05–1 mA). Bronchoalveolar lavage (BAL) fluid was assessed for total and differential cell counts and cytokine levels. Lungs were examined by histopathology and electron microscopy.Key Results: In the HDM mouse asthma model, VNS at intensities equal to or above 0.1 mA (VNS 0.1) but not sham VNS reduced BAL fluid differential cell counts and alveolar macrophages expressing α7 nicotinic receptors (α7nAChR), goblet cell hyperplasia, and collagen deposition. Besides, VNS 0.1 also abated HDM‐induced elevation of type 2 cytokines IL‐4 and IL‐5 and was found to block the phosphorylation of transcription factor STAT6 and expression level of IRF4 in total lung lysates. Finally, VNS 0.1 abrogated methacholine‐induced hyperresponsiveness in asthma mice. Prior administration of α‐bungarotoxin, a specific inhibitor of α7nAChR, but not propranolol, a specific inhibitor of β2‐adrenoceptors, abolished the therapeutic effects of VNS 0.1.Conclusion and Implications: Our data revealed the protective effects of VNS on various clinical features in allergic airway inflammation model. VNS, a clinically approved therapy for depression and epilepsy, appears to be a promising new strategy for controlling allergic asthma.
- Open Access
- 25 April 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (20) , e2203232
Multifunctional Antibacterial Nanonets Attenuate Inflammatory Responses through Selective Trapping of Endotoxins and Pro‐Inflammatory Cytokines
Extracellular lipopolysaccharide (LPS) released from bacteria cells can enter the bloodstream and cause septic complications with excessive host inflammatory responses. Target‐specific strategies to inactivate inflammation mediators have largely failed to improve the prognosis of septic patients in clinical trials. By utilizing their high density of positive charges, de novo designed peptide nanonets are shown to selectively entrap the negatively charged LPS and pro‐inflammatory cytokines tumor necrosis factor‐α (TNF‐α) and interleukin‐6 (IL‐6). This in turn enables the nanonets to suppress LPS‐induced cytokine production by murine macrophage cell line and rescue the antimicrobial activity of the last‐resort antibiotic, colistin, from LPS binding. Using an acute lung injury model in mice, it is demonstrated that intratracheal administration of the fibrillating peptides is effective at lowering local release of TNF‐α and IL‐6. Together with previously shown ability to simultaneously trap and kill pathogenic bacteria, the peptide nanonets display remarkable potential as a holistic, multifunctional anti‐infective, and anti‐septic biomaterial.
- 25 April 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (20) , e2203232
Open AccessMultifunctional Antibacterial Nanonets Attenuate Inflammatory Responses through Selective Trapping of Endotoxins and Pro‐Inflammatory Cytokines
Extracellular lipopolysaccharide (LPS) released from bacteria cells can enter the bloodstream and cause septic complications with excessive host inflammatory responses. Target‐specific strategies to inactivate inflammation mediators have largely failed to improve the prognosis of septic patients in clinical trials. By utilizing their high density of positive charges, de novo designed peptide nanonets are shown to selectively entrap the negatively charged LPS and pro‐inflammatory cytokines tumor necrosis factor‐α (TNF‐α) and interleukin‐6 (IL‐6). This in turn enables the nanonets to suppress LPS‐induced cytokine production by murine macrophage cell line and rescue the antimicrobial activity of the last‐resort antibiotic, colistin, from LPS binding. Using an acute lung injury model in mice, it is demonstrated that intratracheal administration of the fibrillating peptides is effective at lowering local release of TNF‐α and IL‐6. Together with previously shown ability to simultaneously trap and kill pathogenic bacteria, the peptide nanonets display remarkable potential as a holistic, multifunctional anti‐infective, and anti‐septic biomaterial.
- Open Access
- 8 March 2023
- Published by Wiley
Direct vagus nerve stimulation: A new tool to control allergic airway inflammation through α7 nicotinic acetylcholine receptor
Background and Purpose Asthma is characterized by airway inflammation, mucus hypersecretion and airway hyperresponsiveness (AHR). The activation of cholinergic anti‐inflammatory pathway (CAP) through nicotinic agents has been shown to control experimental asthma. Yet, the effects of vagus nerve stimulation (VNS)-induced CAP on allergic inflammation remain unknown. Experimental Approach BALB/c mice were sensitized and challenged with house dust mite (HDM) extract, and treated with active VNS (5Hz, 0.5 ms, 0.1 mA). Bronchoalveolar lavage (BAL) fluid was assessed for total and differential cell counts and cytokine levels. Lungs were examined by histopathology and electron microscopy. AHR in response to methacholine was also measured. Key Results In the HDM mouse asthma model, active but not sham VNS reduced BAL fluid total and differential cell counts, blocked mucus hypersecretion and suppressed choline acetyltransferase (ChAT) expression in bronchial epithelial cells. Besides, active VNS also abated HDM-induced elevation of type 2 cytokines IL-4 and IL-5. Furthermore, goblet cell hyperplasia and collagen deposition were diminished in VNS-treated mice. Mechanistically, VNS was found to block the phosphorylation of transcription factor STAT6 and the level of IRF4 in total lung lysates. Finally, VNS abrogated methacholine-induced AHR in asthma mice. Therapeutic effects of VNS were abolished by prior administration with α-bungarotoxin, a specific inhibitor of α7 nicotinic receptors (α7nAChR). Conclusion Our data revealed the protective effects of VNS on various clinical features in allergic airway inflammation model. VNS, a clinically approved therapy for depression and epilepsy, appears to be a promising new strategy for controlling allergic asthma through α7nAChR.
- 8 March 2023
- Published by Wiley
Open AccessDirect vagus nerve stimulation: A new tool to control allergic airway inflammation through α7 nicotinic acetylcholine receptor
Background and Purpose Asthma is characterized by airway inflammation, mucus hypersecretion and airway hyperresponsiveness (AHR). The activation of cholinergic anti‐inflammatory pathway (CAP) through nicotinic agents has been shown to control experimental asthma. Yet, the effects of vagus nerve stimulation (VNS)-induced CAP on allergic inflammation remain unknown. Experimental Approach BALB/c mice were sensitized and challenged with house dust mite (HDM) extract, and treated with active VNS (5Hz, 0.5 ms, 0.1 mA). Bronchoalveolar lavage (BAL) fluid was assessed for total and differential cell counts and cytokine levels. Lungs were examined by histopathology and electron microscopy. AHR in response to methacholine was also measured. Key Results In the HDM mouse asthma model, active but not sham VNS reduced BAL fluid total and differential cell counts, blocked mucus hypersecretion and suppressed choline acetyltransferase (ChAT) expression in bronchial epithelial cells. Besides, active VNS also abated HDM-induced elevation of type 2 cytokines IL-4 and IL-5. Furthermore, goblet cell hyperplasia and collagen deposition were diminished in VNS-treated mice. Mechanistically, VNS was found to block the phosphorylation of transcription factor STAT6 and the level of IRF4 in total lung lysates. Finally, VNS abrogated methacholine-induced AHR in asthma mice. Therapeutic effects of VNS were abolished by prior administration with α-bungarotoxin, a specific inhibitor of α7 nicotinic receptors (α7nAChR). Conclusion Our data revealed the protective effects of VNS on various clinical features in allergic airway inflammation model. VNS, a clinically approved therapy for depression and epilepsy, appears to be a promising new strategy for controlling allergic asthma through α7nAChR.
- 20 December 2022
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (8) , 1056-1071
Calcaratarin D, a labdane diterpenoid, attenuates mouse asthma via modulating alveolar macrophage function
Background and Purpose: Alveolar macrophages (AMs) contribute to airway inflammation and remodelling in allergic asthma. Calcaratarin D (CalD), a labdane diterpenoid from rhizomes of the medicinal plant Alpinia calcarata, has recently been shown to possess anti‐inflammatory properties. The present study evaluated protective effects of CalD in a house dust mite (HDM)‐induced asthma mouse model.Experimental Approach: The effects of CalD on AMs in contributing to anti‐inflammatory effects in asthma were investigated through in vivo, ex vivo, and in vitro experiments.Key Results: CalD reduced total bronchoalveolar lavage fluid and differential cell count, serum IgE levels, mucus hypersecretion, and airway hyperresponsiveness in HDM‐challenged mice. Additionally, CalD affected a wide array of pro‐inflammatory cytokines and chemokines and oxidative damage markers in isolated lung tissues. CalD suppressed the HDM‐induced increase in Arg1 (M2 macrophage marker) in AMs from lung tissue and reduced lung polyamine levels. CalD weakened antigen presentation capability of AMs by reducing CD80 expression, reduced AM‐derived CCL17 and CCL22 levels, and lessened Th2 cytokines from CD4+ T‐cells from asthma lung digest. CalD blocked the HDM‐induced FoxO1/IRF4 pathway and restored impaired the Nrf2/HO‐1 antioxidant pathway in lung tissues. CalD inhibited IL‐4/IL‐13‐stimulated JAK1/STAT6 pathway, FoxO1 protein expression, and chemokine production in primary AMs. Structure–activity relationship study revealed the α,β‐unsaturated γ‐butyrolactone in CalD is capable of forming covalent bonds with cellular protein targets essential for its action.Conclusion and Implications: Our results demonstrate for the first time that CalD is a novel anti‐inflammatory natural compound for allergic asthma that modulates AM function.
- 20 December 2022
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (8) , 1056-1071
Calcaratarin D, a labdane diterpenoid, attenuates mouse asthma via modulating alveolar macrophage function
Background and Purpose: Alveolar macrophages (AMs) contribute to airway inflammation and remodelling in allergic asthma. Calcaratarin D (CalD), a labdane diterpenoid from rhizomes of the medicinal plant Alpinia calcarata, has recently been shown to possess anti‐inflammatory properties. The present study evaluated protective effects of CalD in a house dust mite (HDM)‐induced asthma mouse model.Experimental Approach: The effects of CalD on AMs in contributing to anti‐inflammatory effects in asthma were investigated through in vivo, ex vivo, and in vitro experiments.Key Results: CalD reduced total bronchoalveolar lavage fluid and differential cell count, serum IgE levels, mucus hypersecretion, and airway hyperresponsiveness in HDM‐challenged mice. Additionally, CalD affected a wide array of pro‐inflammatory cytokines and chemokines and oxidative damage markers in isolated lung tissues. CalD suppressed the HDM‐induced increase in Arg1 (M2 macrophage marker) in AMs from lung tissue and reduced lung polyamine levels. CalD weakened antigen presentation capability of AMs by reducing CD80 expression, reduced AM‐derived CCL17 and CCL22 levels, and lessened Th2 cytokines from CD4+ T‐cells from asthma lung digest. CalD blocked the HDM‐induced FoxO1/IRF4 pathway and restored impaired the Nrf2/HO‐1 antioxidant pathway in lung tissues. CalD inhibited IL‐4/IL‐13‐stimulated JAK1/STAT6 pathway, FoxO1 protein expression, and chemokine production in primary AMs. Structure–activity relationship study revealed the α,β‐unsaturated γ‐butyrolactone in CalD is capable of forming covalent bonds with cellular protein targets essential for its action.Conclusion and Implications: Our results demonstrate for the first time that CalD is a novel anti‐inflammatory natural compound for allergic asthma that modulates AM function.
- Open Access
- 15 February 2022
- Published by Wiley
A unique CD27 - IgD - B-cells population in the sputum of severe eosinophilic asthma associated with airway autoimmunity
- 15 February 2022
- Published by Wiley
Open AccessA unique CD27 - IgD - B-cells population in the sputum of severe eosinophilic asthma associated with airway autoimmunity
- Open Access
- 19 January 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (4)
ISM1 protects lung homeostasis via cell-surface GRP78-mediated alveolar macrophage apoptosis
Significance: Inflammation regulation and homeostasis maintenance is of paramount importance for lung health. Using both genetic and pathological mouse models, this work reveals that the secreted proapoptotic isthmin 1 (ISM1) protects lung homeostasis by controlling alveolar macrophage (AM) population and functional phenotype via cell-surface GRP78 (csGRP78)-mediated apoptosis. In both mouse and human, AMs express varied amount of csGRP78, enabling ISM1 to selectively remove the proinflammatory csGRP78 high AMs via apoptosis. In cigarette smoke–induced chronic obstructive pulmonary disease (COPD) mice, pulmonary delivery of recombinant ISM1 (rISM1) suppressed lung inflammation, blocked emphysema development, and preserved lung function. This work reveals molecular insights for lung homeostasis regulation and offers a rationale to target csGRP78 with pulmonary-delivered rISM1 as a potential therapeutic strategy for COPD.
- 19 January 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (4)
Open AccessISM1 protects lung homeostasis via cell-surface GRP78-mediated alveolar macrophage apoptosis
Significance: Inflammation regulation and homeostasis maintenance is of paramount importance for lung health. Using both genetic and pathological mouse models, this work reveals that the secreted proapoptotic isthmin 1 (ISM1) protects lung homeostasis by controlling alveolar macrophage (AM) population and functional phenotype via cell-surface GRP78 (csGRP78)-mediated apoptosis. In both mouse and human, AMs express varied amount of csGRP78, enabling ISM1 to selectively remove the proinflammatory csGRP78 high AMs via apoptosis. In cigarette smoke–induced chronic obstructive pulmonary disease (COPD) mice, pulmonary delivery of recombinant ISM1 (rISM1) suppressed lung inflammation, blocked emphysema development, and preserved lung function. This work reveals molecular insights for lung homeostasis regulation and offers a rationale to target csGRP78 with pulmonary-delivered rISM1 as a potential therapeutic strategy for COPD.
- 25 April 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (16) , 3662-3673
Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease
Background and Purpose: Corticosteroid resistance poses a major barrier to an effective anti‐inflammatory therapy for chronic obstructive pulmonary disease (COPD). The present study aimed to investigate potential corticosteroid re‐sensitization actions of andrographolide, a bioactive molecule from the herb Andrographis paniculata, in COPD models, particularly in peripheral blood mononuclear cells (PBMCs) from COPD patients.Experimental Approach: Corticosteroid sensitivity in PBMCs collected from COPD patients, or in human monocytic U937 cells exposed to cigarette smoke extract (CSE), was determined by measuring LPS‐induced IL‐8 production, in the presence and absence of andrographolide. The mechanisms of corticosteroid re‐sensitization action of andrographolide were evaluated in a mouse cigarette smoke (CS)‐induced acute lung injury model.Key Results: Impaired inhibition of IL‐8 production by dexamethasone was detected in PBMCs from COPD patients and in CSE‐exposed U937 cells, together with reduced levels of nuclear factor erythroid 2‐related factor 2 (Nrf2) and histone deacetylase‐2 (HDAC2). In both PBMCs and CSE‐exposed U937 cells, andrographolide restored dexamethasone inhibition of IL‐8 production, accompanied by the up‐regulation of Nrf2 and HDAC2 levels. In the U937 cells, andrographolide was able to block CSE‐induced Akt and reduce the level of c‐Jun. Besides, andrographolide also augmented dexamethasone actions on lowering total and neutrophil counts, cytokine levels, and oxidative damage markers in bronchoalveolar lavage fluid from CS‐exposed mice.Conclusion and Implications: We report here for the first time a novel corticosteroid re‐sensitization property of andrographolide in human PBMCs and provide mechanistic evidence to support clinical evaluation of andrographolide in reversing steroid resistance in COPD.
- 25 April 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (16) , 3662-3673
Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease
Background and Purpose: Corticosteroid resistance poses a major barrier to an effective anti‐inflammatory therapy for chronic obstructive pulmonary disease (COPD). The present study aimed to investigate potential corticosteroid re‐sensitization actions of andrographolide, a bioactive molecule from the herb Andrographis paniculata, in COPD models, particularly in peripheral blood mononuclear cells (PBMCs) from COPD patients.Experimental Approach: Corticosteroid sensitivity in PBMCs collected from COPD patients, or in human monocytic U937 cells exposed to cigarette smoke extract (CSE), was determined by measuring LPS‐induced IL‐8 production, in the presence and absence of andrographolide. The mechanisms of corticosteroid re‐sensitization action of andrographolide were evaluated in a mouse cigarette smoke (CS)‐induced acute lung injury model.Key Results: Impaired inhibition of IL‐8 production by dexamethasone was detected in PBMCs from COPD patients and in CSE‐exposed U937 cells, together with reduced levels of nuclear factor erythroid 2‐related factor 2 (Nrf2) and histone deacetylase‐2 (HDAC2). In both PBMCs and CSE‐exposed U937 cells, andrographolide restored dexamethasone inhibition of IL‐8 production, accompanied by the up‐regulation of Nrf2 and HDAC2 levels. In the U937 cells, andrographolide was able to block CSE‐induced Akt and reduce the level of c‐Jun. Besides, andrographolide also augmented dexamethasone actions on lowering total and neutrophil counts, cytokine levels, and oxidative damage markers in bronchoalveolar lavage fluid from CS‐exposed mice.Conclusion and Implications: We report here for the first time a novel corticosteroid re‐sensitization property of andrographolide in human PBMCs and provide mechanistic evidence to support clinical evaluation of andrographolide in reversing steroid resistance in COPD.